Report Highlights

The United States' Role in the Global Gene Synthesis Supply Chain

The United States is the dominant producer of commercial synthetic DNA, with a cluster of foundries concentrated in the San Francisco Bay Area, San Diego, and Iowa. Twist Bioscience's South San Francisco facilities and Integrated DNA Technologies' Coralville plant account for a large share of global clonal gene and oligo pool output. Domestic providers export finished constructs to Germany, the United Kingdom, Japan, and Singapore, while importing enzymes, nucleotide precursors, and synthesis columns from Europe and Asia.

Import dependence is concentrated in upstream chemistry rather than finished output. Phosphoramidites, controlled-pore glass, and high-fidelity polymerases arrive principally through Chinese and Indian chemical intermediates and German reagent houses, routed via the ports of Newark, Los Angeles, and Oakland. The U.S. therefore holds a value-added position in design, sequence verification, and assembly, while its vulnerability sits in the reagent inputs that every domestic foundry consumes.

Growth Drivers for U.S. Gene Synthesis Trade and Production

Biopharmaceutical pipelines drive the strongest capacity expansion. mRNA vaccine and cell therapy programs require long, sequence-verified constructs, and Ginkgo Bioworks' Boston foundry and Twist's Bay Area expansions have added throughput aimed at this demand. Ansa Biotechnologies' enzymatic platform, which produces longer fragments with reduced solvent consumption, is pulling capacity toward genes exceeding 5,000 base pairs.

Federal research funding and AI-driven protein design create a second demand stream. Machine learning-guided protein engineering generates pools of tens of thousands of designed sequences per campaign, favoring oligo pool suppliers such as Twist and Agilent. Reshoring of pharmaceutical manufacturing under Section 232 investigations is also prompting domestic buyers to replace offshore gene vendors with U.S.-based providers, substituting imports with domestic output.

Supply Chain Risks and Trade Barriers

Raw material dependency represents the most acute exposure. Chemical intermediates for phosphoramidite synthesis carry concentrated Chinese sourcing, and the 2025 expansion of tariffs on Chinese imports raised landed costs for reagent shipments entering through Los Angeles and Long Beach. Providers without domestic chemical inventory face margin compression and delivery slippage on customer orders, particularly for time-sensitive clinical programs.

Export controls and biosecurity screening create the second risk layer. The 2024 OSTP Framework for Nucleic Acid Synthesis Screening requires federally funded purchasers to buy from screened providers, while Commerce Department controls on certain biotechnology equipment restrict exports of advanced synthesizers. Logistics gaps compound these pressures, since cold-chain shipping of lyophilized oligos depends on a limited number of FedEx and UPS hubs in Memphis and Louisville.

Trade and Investment Opportunities in the United States

Import substitution represents the clearest commercial opening. Domestic phosphoramidite and enzyme manufacturing, currently concentrated in a handful of German and Chinese suppliers, can be reshored into existing biomanufacturing zones such as the Research Triangle in North Carolina and the Boston-Cambridge corridor. Investors backing reagent plants there would capture the margin now flowing to offshore intermediates.

Logistics hub development and export expansion offer parallel upside. Memphis, Louisville, and Indianapolis, which host FedEx and UPS hubs, can position as temperature-controlled export nodes for synthetic DNA shipped to Europe and Asia-Pacific. Inbound FDI from Japanese and Korean pharmaceutical groups seeking U.S.-sourced constructs for their own pipelines strengthens the case for domestic foundry expansion.

Market at a Glance

Leading Market Participants

• Twist Bioscience
• Integrated DNA Technologies
• Ansa Biotechnologies
• Elegen
• Telesis Bio
• Ginkgo Bioworks
• Agilent Technologies
• Thermo Fisher Scientific
• Azenta Life Sciences
• Synthego

Regulatory and Trade Policy Framework for U.S. Gene Synthesis

Trade policy operates through tariffs, export controls, and procurement rules. Chinese-origin reagents and intermediates face Section 301 duties plus additional tariffs imposed under IEEPA in 2025, while Mexican-origin inputs qualify for preferential treatment under USMCA when origin rules are met. Commerce's Bureau of Industry and Security administers Export Administration Regulations covering certain synthesizers and sequence-related technology, and the Trade Agreements Act governs federal procurement eligibility.

Biosecurity regulation shapes the investment climate. The 2024 OSTP framework and subsequent federal revisions require customers to be screened and sequences checked against sequence-of-concern databases, while BIOSECURE Act provisions target contracting with specified Chinese biotechnology providers. Compliance screening adds cost but also creates a procurement advantage for domestic providers with established verification systems.

U.S. Gene Synthesis Supply Chain Outlook to 2032

Enzymatic and benchtop synthesis will reshape comparative advantage by 2032. Enzymatic platforms reduce dependence on phosphoramidite feedstock, shifting value toward enzyme formulation and terminal transferase supply, where U.S. suppliers such as New England Biolabs in Ipswich, Massachusetts hold established positions. This transition lowers the strategic weight of Asian chemical intermediates in domestic output.

Trade flows will tilt toward exports of sequence-verified constructs and away from raw oligo imports. U.S. providers will increasingly serve European and Asia-Pacific pharmaceutical pipelines from domestic plants, while Chinese providers face sustained restrictions in federal procurement. The market reaches USD 2.62 billion in 2032 on this trajectory, with domestic capacity filling the gap left by offshore reagent suppliers.